mutant KRASG12C allosteric covalent inhibitor

orally efficacious in XG model

from optimization of literature starting point

J. Med. Chem. Feb. 5, 2020

AstraZeneca, Cambridge, UK

"compound 25"

KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: